BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
$16.41
-$0.31(-5.78%)
At close: 4:00 PM EST
$16.41
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$2.88 - $24.00
Previous CloseN/A
Volume146.35K
Average Volume (3M)573.23K
Market Cap
$728.27M
Enterprise Value$405.05M
Total Cash (Recent Filing)$281.10M
Total Debt (Recent Filing)$5.56M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 12, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding44,379,753
10 Day Avg. Volume745,648
30 Day Avg. Volume573,234
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue45.03
Enterprise Value/Gross Profit45.38
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
$47.63Price Target Upside190.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.76
Revenue Forecast (FY)$3.72M
Bulls Say, Bears Say
Bulls Say
Biomarker Differentiation And MechanismRobust reductions in inflammatory biomarkers such as IL-1β and hsCRP, combined with oral, brain-penetrant properties and a unique binding mechanism, suggest differentiated clinical potential versus existing therapies.
Financing And Upcoming Clinical CatalystsAn upsized follow-on public offering strengthened cash resources, supporting planned catalysts like full Phase 1 data release and initiation of a placebo-controlled Phase 2a study that could clarify clinical prospects.
Ophthalmology ExpansionExpansion of BGE-102 development into ophthalmology leverages retina penetration and preclinical retinal efficacy, creating an additional commercial opportunity beyond cardiometabolic indications.
Bears Say
Development And Execution RiskAnalyst's High Risk designation highlights substantial development, regulatory, financing, and commercial risks that could negatively affect progress and market prospects if key milestones are not met.
Potential Conflicts Of Interest In CoverageDisclosure that the reporting firm may have business relationships with covered companies raises concerns about objectivity and could reduce confidence in analyst-driven positive sentiment.
Retinal Proof-of-concept RequirementA required proof-of-concept study in diabetic macular edema is a critical development hurdle; failure to demonstrate retinal impact from oral dosing would weaken the ophthalmology expansion case.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $24.00 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $728.27M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is May 12, 2026 which is in 47 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.738 by $0.018.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.63.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 44,379,753 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.738. Following the earnings report the stock price went up 8.678%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.63 (190.25% Upside)
$47.63 (190.25% Upside)
Blogger Sentiment
Bearish
BIOA Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.7%
Last 30 Days ▲ 28.2%
Last 30 Days ▲ 28.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
254.84%
12-Months-Change
Fundamentals
Return on Equity
-27.86%
Trailing 12-Months
Asset Growth
-17.52%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$47.63
▲(190.25% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
10.17% Insiders
5.41% Mutual Funds
36.41% Other Institutional Investors
40.40% Public Companies and
Individual Investors